The Pulse Newsletter Expert heart health, in plain English. Fortnightly, from our clinicians. Subscribe →

The Nuclear Stress Test: What It Is, What to Expect, and Why It’s Requested

Key Points

  • A nuclear stress test, also called myocardial perfusion imaging (MPI), uses a small amount of radioactive tracer to produce detailed images of blood flow through the heart muscle at rest and during stress.
  • It shows not just whether the heart is receiving adequate blood supply, but precisely which areas of muscle are affected and to what degree, making it particularly useful for planning treatment after a heart attack or assessing complex coronary disease.
  • The radiation dose is low and the tracer clears from the body within hours. The test is safe and well-tolerated.
  • For patients who cannot exercise, a pharmacological stress agent is used to mimic the effect of exertion on the heart, making the test accessible regardless of physical capacity.
  • The nuclear stress test is typically requested when other investigations have not provided sufficient information, or when a more detailed map of myocardial perfusion is needed for clinical decision-making.

Most people who are investigated for chest pain or breathlessness will have a stress echocardiogram or CT coronary angiogram as their functional or anatomical assessment. But there is a subset of clinical questions where a more detailed map of blood flow through the heart muscle, not just whether flow is reduced, but precisely where and by how much, changes the clinical decision. That is where myocardial perfusion imaging comes in.

The nuclear stress test is less commonly performed than other cardiac investigations, but when it is requested it is usually for a specific and well-considered reason. Understanding what it involves and what it provides helps patients approach it with appropriate expectations.

What Is a Nuclear Stress Test?

Myocardial perfusion imaging

A nuclear stress test, formally called myocardial perfusion imaging (MPI) or radionuclide stress testing, uses a small amount of a radioactive tracer injected into a vein. This tracer travels through the bloodstream and is taken up by the heart muscle in proportion to blood flow. Areas receiving good blood supply absorb more tracer; areas with reduced flow absorb less.

A specialised camera, called a gamma camera or SPECT scanner, then detects the radiation emitted by the tracer and produces detailed images of the distribution of blood flow through the heart muscle. Images are taken at rest and during stress, and the two sets are compared.

What it can show

Where a stress echocardiogram detects wall motion abnormalities as an indirect consequence of reduced blood flow, myocardial perfusion imaging detects the reduced flow directly. This makes it particularly sensitive for identifying ischaemia, reduced blood supply to the heart muscle during stress, and for mapping its extent and distribution with precision.

It can also distinguish between viable heart muscle that is simply underperfused, and therefore potentially recoverable, and permanently scarred tissue from a previous heart attack that will not recover regardless of intervention. This distinction is clinically important when deciding whether revascularisation is likely to benefit a patient.

When Is It Requested?

The nuclear stress test occupies a specific niche in the cardiac investigation toolkit. It is typically requested in clinical situations where other investigations have not provided sufficient information, or where the level of anatomical and functional detail it provides is specifically needed.

Common indications include assessment of known coronary artery disease where the functional significance of a narrowing needs to be established; evaluation of myocardial viability after heart attack to determine whether revascularisation is likely to improve function; investigation of chest symptoms in patients with complex anatomy, such as previous bypass surgery, where standard stress testing may be less reliable; and risk stratification in patients with known coronary disease prior to non-cardiac surgery.

What to Expect, Nuclear Stress Test

Duration

3–4 hours in total across the appointment, including rest imaging, stress phase, and post-stress imaging. Some protocols split rest and stress imaging across two days.

Preparation

Fast for 4–6 hours before the test. Avoid caffeine for 24–48 hours, caffeine interferes with pharmacological stress agents. Some medications may need to be withheld, your team will advise specifically. Wear comfortable clothing and walking shoes.

Comfort

A cannula is placed in a vein in the arm for the tracer injection. The imaging involves lying still on a scanner table with the camera rotating around the chest, this is not enclosed and is well-tolerated. The pharmacological stress agent may cause a brief flushing sensation or mild breathlessness that resolves quickly.

Radiation

A small amount of radioactive tracer is used. The effective radiation dose is typically 3–10 mSv, comparable to a CT coronary angiogram. The tracer clears from the body within hours to a day. No special precautions are required afterwards.

Results

Images require specialist nuclear cardiology reporting. Results are typically available within a few days and discussed with you by your referring cardiologist at follow-up.

Afterwards

No restrictions on activity. Drink plenty of water to help the tracer clear. If you had a pharmacological stress agent, any transient symptoms resolve quickly, you will be monitored until they do.

Exercise vs Pharmacological Stress

Exercise stress

Where possible, physical exercise on a treadmill or exercise bike is the preferred method of inducing stress, it produces the most physiologically meaningful assessment and also provides additional information about exercise capacity, heart rate response, and blood pressure behaviour during exertion.

Pharmacological stress

For patients who cannot exercise adequately, due to orthopaedic limitations, severe deconditioning, peripheral vascular disease, or other reasons, a pharmacological stress agent is used instead. Adenosine, regadenoson, or dobutamine are the most commonly used agents. They work by dilating the coronary arteries or increasing heart rate and myocardial demand, mimicking the effect of exercise on blood flow distribution.

Caffeine blocks the effect of adenosine-based agents, which is why avoiding coffee, tea, and other caffeine sources for 24 to 48 hours before the test is essential if a pharmacological stress protocol is planned. Your team will confirm the specific requirements.

How It Compares to Other Tests

Test What it shows Radiation Best used for
Stress echocardiogram Wall motion, indirect marker of ischaemia None First-line functional assessment, valve assessment under load
CT coronary angiogram Coronary artery anatomy, degree of narrowing Low (3–10 mSv) Ruling out significant coronary disease, anatomical planning
Nuclear stress test (MPI) Blood flow distribution through heart muscle Low–moderate (3–10 mSv) Detailed perfusion mapping, viability assessment, complex CAD
Cardiac MRI stress test Perfusion and function, no radiation None Detailed perfusion without radiation, increasingly used
Invasive coronary angiogram Direct coronary anatomy, gold standard Low (radiation from X-ray) Definitive diagnosis with option to treat in same session

About the Radiation

The word “nuclear” in nuclear stress test refers to the radioactive tracer, not to the type of energy or any risk analogous to nuclear power. The tracers used are specifically designed for rapid clearance from the body and produce a radiation dose that, while slightly higher than a CT coronary angiogram, remains well within accepted safety parameters for a single diagnostic test.

To put it in context, the effective dose from a nuclear stress test is roughly equivalent to one to three years of natural background radiation from the environment. The clinical benefit of accurate diagnosis in the situations where a nuclear stress test is requested far outweighs this level of exposure.

When I request a nuclear stress test, it is usually because I want more information than other investigations have provided, specifically, I want to know not just whether there is ischaemia, but where it is and how much muscle is affected. That precision changes decisions. It can be the difference between recommending revascularisation and recommending optimised medical therapy.

— Prof. Peter Barlis, Interventional Cardiologist

Questions worth asking about your nuclear stress test

  • Why is a nuclear stress test being requested rather than a stress echo or CTCA, what specifically does it add?
  • Will I be exercising or having a pharmacological stress agent, and does caffeine avoidance apply to me?
  • Which medications do I need to withhold before the test?
  • What will the results tell you that you don’t already know from my other investigations?
  • Is cardiac MRI an alternative that could provide similar information without radiation?

Heart Matters Resource

When in Doubt, Get Checked Out

If you have been referred for a nuclear stress test and want to understand why, or what the result will mean for your management, that conversation with your cardiologist before the test is worth having.

Read: When in Doubt, Get Checked Out →

Conclusion

The nuclear stress test is a specialised investigation that provides a level of detail about myocardial blood flow that other non-invasive tests cannot match. When the clinical question requires knowing not just whether ischaemia is present, but where and how much muscle is affected, or whether damaged heart muscle is still viable, myocardial perfusion imaging provides the answer.

The radiation involved is modest and the procedure is well-tolerated. The length of the appointment, typically three to four hours, is the main practical consideration, and knowing to expect this in advance makes the day considerably less uncertain.

If you have been referred for this test, it is because your cardiologist needs a specific type of information to guide your management. That information will shape the next clinical decision, and that is exactly what a good investigation should do.

More from Heart Matters, Diagnostic Tests

What Is Clopidogrel Used For?

heartmatters.com 2026 04 02T052736.709

Clopidogrel is one of the most widely prescribed heart medicines in the world. Here is how it works, what it is used for, and everything you need to know about taking it safely.

Is There Something Fishy About Fish Oil?

heartmatters.com 2026 04 05T090155.280

A recent study links regular fish oil supplements to increased cardiovascular risk in people without pre-existing heart disease. Here is what the findings mean for you.

HFrEF and HFpEF: Understanding the Two Types of Heart Failure

heartmatters.com 2026 04 01T171429.222
Key Points

  • Heart failure does not mean the heart has stopped, it means the heart is not pumping as efficiently as it should, and cannot fully keep up with the body’s demands.
  • Doctors describe heart failure in two main ways, based on whether the heart’s pumping strength is reduced or whether it is normal but the heart has become stiff. Both cause similar symptoms.
  • The term “ejection fraction” refers to the percentage of blood the heart pumps out with each beat. A normal ejection fraction is above 55%. In heart failure with reduced ejection fraction it is below 40%.
  • HFrEF, heart failure with reduced ejection fraction, means the heart muscle is pumping less powerfully than normal. HFpEF, heart failure with preserved ejection fraction, means the pumping strength appears normal but the heart has become stiff and does not fill properly between beats.
  • Both types are treatable. The specific medications and management approach differ between the two, which is why knowing which type you have matters for your treatment plan.

Being told you have heart failure is frightening enough. Being told you have “HFrEF” or “HFpEF”, or that your ejection fraction is reduced or preserved, adds a layer of medical terminology that can leave patients more confused than informed.

These terms are important, they describe which type of heart failure you have and directly influence which treatments are most appropriate for you. But they are not complicated once they are explained in plain language. This article does exactly that.

What Is Ejection Fraction?

The heart is a pump. With every beat, it squeezes blood out of its main pumping chamber, the left ventricle, and sends it out to the rest of the body. The ejection fraction is simply the percentage of blood in that chamber that gets pumped out with each beat.

It is measured using an echocardiogram, an ultrasound of the heart that shows how the heart muscle is moving and how much blood is being pumped with each beat. It is one of the most important single measurements in cardiology.

In a healthy heart, the left ventricle pumps out roughly 55 to 70% of the blood it contains with each squeeze. This is a normal ejection fraction. The remaining blood stays in the ventricle and is topped up again as the heart relaxes and refills before the next beat.

When the heart muscle is weakened, as happens in certain types of heart failure, it squeezes less powerfully, and a smaller percentage of blood is pumped out with each beat. This is what a reduced ejection fraction means.

The Two Main Types of Heart Failure

HFrEF, Heart Failure with Reduced Ejection Fraction

In HFrEF, pronounced “HF-ref”, the heart muscle has weakened and is not squeezing as powerfully as it should. The ejection fraction is below 40%, meaning less than 40% of the blood in the left ventricle is being pumped out with each beat. The heart is working hard but not achieving enough forward output.

The symptoms this produces, breathlessness, fatigue, ankle swelling, reduced exercise tolerance, reflect the fact that the body’s tissues are not receiving as much blood and oxygen as they need. The heart compensates as best it can, but over time the gap between what the body demands and what the heart can deliver produces the characteristic symptoms of heart failure.

HFrEF has an excellent range of treatments available, in fact the evidence base for treating HFrEF is one of the strongest in all of cardiology. A combination of four medication classes, known as quadruple therapy, including SGLT2 inhibitors, beta-blockers, ACE inhibitors, and mineralocorticoid receptor antagonists has been shown to significantly improve both symptoms and long-term outcomes. We cover this in detail in our dedicated heart failure treatment article.

HFpEF, Heart Failure with Preserved Ejection Fraction

In HFpEF, pronounced “HF-pef”, the heart’s pumping strength appears normal on an echocardiogram. The ejection fraction is above 50%, meaning the heart is squeezing well. But the patient still has heart failure symptoms, breathlessness, fatigue, reduced exercise capacity, because something else is going wrong.

The problem in HFpEF is stiffness. The heart muscle has become less flexible, it does not relax and fill between beats as easily as it should. Think of squeezing a stiff rubber ball compared to a soft one, the stiff ball takes more effort to compress and springs back less readily. When the heart muscle is stiff, it fills less efficiently between beats, pressures rise within the heart, and those elevated pressures back up into the lungs, producing breathlessness and the other symptoms of heart failure despite normal pumping strength.

HFpEF is more common in older patients, women, people with high blood pressure, obesity, and diabetes. Managing the underlying conditions that contribute to cardiac stiffness, blood pressure control, weight management, blood sugar control, is a central part of HFpEF treatment alongside specific medications.

55%+
A normal ejection fraction is above 55%, meaning the heart pumps out more than half the blood in its main chamber with every beat. Below 40% is considered reduced. Between 40% and 55% is sometimes called mildly reduced or borderline.

Why Does the Distinction Matter?

The two types of heart failure produce very similar symptoms, which is why an echocardiogram is needed to distinguish them rather than clinical assessment alone. But the treatment approaches differ in important ways.

The medications that have the strongest evidence in HFrEF, particularly certain beta-blockers, ACE inhibitors, and SGLT2 inhibitors, have been studied extensively in that specific population and shown to improve outcomes significantly. HFpEF research has historically lagged behind, but SGLT2 inhibitors have now shown meaningful benefit in HFpEF as well, and the treatment landscape is improving rapidly.

Knowing which type you have means your clinical team can apply the right evidence to your specific situation. Regular follow-up including BNP or NT-proBNP blood tests helps the clinical team monitor how hard the heart is working and whether treatment is achieving the right effect.

When a patient is told they have heart failure, one of the first questions I want answered is which type, because the management pathway differs. An echocardiogram gives us that answer quickly, and it changes the conversation about which treatments are most likely to help.

— Prof. Peter Barlis, Interventional Cardiologist

A Note on Borderline Ejection Fraction

Some patients are told their ejection fraction is “mildly reduced” or “borderline”, typically a reading between 40% and 55%. This sits between the two main categories and is sometimes called HFmrEF, heart failure with mildly reduced ejection fraction. It shares features of both types and is managed on an individualised basis. If you have been given this term and are unsure what it means for your treatment, asking your cardiologist to clarify which treatment approach applies to you is a very reasonable question.

What Both Types Have in Common

Regardless of which type of heart failure you have, the broader management principles are similar, monitoring symptoms, daily weighing to detect fluid accumulation early, appropriate exercise within your limits, salt and fluid awareness, and regular follow-up with your clinical team.

Understanding which type of heart failure you have is the starting point, not the end of the conversation. The most important next step is working with your cardiologist to ensure your treatment is optimised for your specific type, your specific symptoms, and your specific circumstances. We cover all of these management approaches in detail in our heart failure treatment article.

Questions worth asking at your next appointment

  • Which type of heart failure do I have, HFrEF or HFpEF, and what does that mean for my treatment?
  • What is my ejection fraction, and has it changed since my last echocardiogram?
  • Am I on the right medications for my specific type of heart failure?
  • Are there conditions contributing to my heart failure, blood pressure, diabetes, weight, that we should be managing more aggressively?
  • What symptoms should prompt me to contact the team between appointments?

Heart Matters Resource

When in Doubt, Get Checked Out

If you have been told you have heart failure and are not sure which type, or if your symptoms have changed, that is a conversation worth having with your cardiologist promptly rather than waiting for the next routine appointment.

Read: When in Doubt, Get Checked Out →

Conclusion

HFrEF and HFpEF are not two different diseases, they are two different mechanisms by which the heart fails to meet the body’s demands. One involves a weakened pump, the other a stiff one. Both produce similar symptoms, both are diagnosed with an echocardiogram, and both are treatable, though the specific treatment approaches differ.

Knowing which type you have puts you in a stronger position to understand your treatment and ask the right questions at your appointments. It is not a label to be feared, it is a piece of information that your clinical team uses to make your management as targeted and effective as possible.

Your heart has two ways of struggling, and medicine has effective answers for both.

More from Heart Matters